Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Clinical trial NCT02314052 · TERMINATED
Trial details
- NCT number
- NCT02314052
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-27
- Primary completion
- 2016-10-11
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.